ArticleChinese medical journal2018
Pelvic Exenteration for Recurrent and Persistent Cervical Cancer.
Article in Chinese medical journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03291275 (Survival Outcomes of Uterine Malignancies in Chinese Population), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Survival Outcomes of Uterine Malignancies in Chinese Population
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Evaluation of survival and mortality in pelvic exenteration for gynecologic malignancies: a systematic review, meta-analyses, and meta-regression study.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025Pooled it
- A systematic review and meta-analysis on mortality rate following total pelvic exenteration in cancer patients.BMC cancer · 2024Pooled it
- Historical Evolution of Pelvic Exenteration Surgery in Gynecologic Cancers: A Systematic Review and Meta-Analysis of Brunschwig's Era versus Contemporary Practice.Annals of surgical oncology · 2026Review
- Advances in the Surgical Management of Cervical Cancer.Cancers · 2026Review
- Article
- Review
- Controversies and Advances in the Personalized Surgical Treatment of Cervical Cancer.Journal of personalized medicine · 2024Review
- Re-Irradiation with Intensity-Modulated Radiation Therapy for the Treatment of Recurrent Cervical Cancer in the Pelvis: An Analysis of Outcomes and Toxicity.Medicina (Kaunas, Lithuania) · 2023Article
- Salvage Treatment and Outcomes of Locally Advanced Cervical Cancer after Failed Concurrent Chemoradiation with or without Adjuvant Chemotherapy: Post Hoc Data Analysis from the ACTLACC Trial.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Long-Term Survival, Prognostic Factors, and Quality of Life of Patients Undergoing Pelvic Exenteration for Cervical Cancer.Cancers · 2022Article
- Pelvic Exenteration for the Treatment of Locally Advanced Vulvar Cancer in South West Wales.Cancers · 2022Article
- Bevacizumab increases late toxicity in re-irradiation with image-guided high-dose-rate brachytherapy for gynecologic malignancies.Journal of contemporary brachytherapy · 2022Article
- Primary pelvic exenteration: Our experience with 23 patients from a single institution.Experimental and therapeutic medicine · 2021Article
- Radiotherapy for Vaginal Recurrences of Cervical Cancer in Patients After Prior Surgery: Analysis of Effect and Prognostic Factors.Frontiers in oncology · 2021Article
- Selection of Treatment Regimens for Recurrent Cervical Cancer.Frontiers in oncology · 2021Article
- Analysis of long-term outcomes in 44 patients following pelvic exenteration due to cervical cancer.World journal of surgical oncology · 2020Article
- Dosimetry comparison between a 3D printed minimally invasive guidance template and free implantation in the brachytherapy treatment of postoperative recurrent cervical carcinoma.Cancer management and research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPelvic exenteration (PE) for primary and recurrent cervical cancer has resulted in favorable survival outcomes, but there are controversies about specific prognosis factors, and up to now, there have been no published reports from China. This study aimed to share our experiences of PE, which were performed in a single institution.
methodsFrom January 2009 to January 2016, 38 patients with recurrent or persistent cervical cancer were included in the study, and they were followed up until January 2017. Epidemiological and clinicopathological characteristics of patients were compared for survival outcomes in univariate and Cox hazard regression analysis.
resultsThere were thirty-one and seven patients with recurrent and persistent cervical cancer, respectively. The median age of patients was 45 years (range 29-65 years). Total, anterior, and posterior PE consisted of 52.6%, 28.9%, and 18.4% of cases, respectively. Early and late complications occurred in 21 (55.3%) patients and 15 (39.5%) patients, respectively. Two (5.3%) patients died due to complications related to surgeries within 3 months after PE. The median overall survival (OS) and disease-free survival (DFS) were 28.5 months (range 9-96 months) and 23 months (range 4-96 months), respectively, and 5-year OS and DFS were 48% and 40%, respectively. Cox hazard regression analysis showed that, the margin status of the incision and mesorectal lymph node status were independent risk factors for OS and DFS.
conclusionIn our patients with recurrent and persistent cervical cancer, the practice of PE might achieve favorable survival outcomes.
trial registrationClinicalTrials.gov, NCT03291275; https://clinicaltrials.gov/ct2/show/NCT03291275?term=NCT03291275&rank=1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.